TITLE

Clot-fighting Drug Plavix Loses Patent Protection

PUB. DATE
May 2012
SOURCE
MondayMorning;5/21/2012, Vol. 20 Issue 21, p1
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article informs that the drug Plavix, which had been prescribed by cardiologists to patients having heart attack for more than a decade, has lost its patent protection. It has been informed that Bristol-Myers Squibb Co., which sells Plavix in the U.S. under a partnership with Sanofi SA, has decided not to actively promote the drug due to influx of cheaper generic alternatives.
ACCESSION #
75653511

 

Related Articles

  • Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex.  // Biomedical Market Newsletter;2/14/2012, Vol. 21, p1 

    The article informs that the companies Sanofi SA and Bristol-Myers Squibb Co. announced Apotex Corp. has made certain payments to these companies for satisfying the damages ruled in the litigation based on Plavix(r) which is a clopidogrel based patent infringement case filed against Apotex. The...

  • Bristol-Myers Squibb case study.  // Bristol-Myers Squibb Case Study: Overcoming the threat from gene;Oct2005, p1 

    Presents a case study of the preparations taken by Bristol-Myers Squibb for the threats posed by the development of generic antidiabetics. Background of the establishment of the company; Challenges faced by the firm concerning the launch of its Glucophage XR; Details of patent infringement...

  • Bristol-Myers Squibb: searching for a new direction.  // PharmaWatch: Monthly Review;Oct2006, Vol. 5 Issue 10, p17 

    The article presents information on the ouster of chief executive Peter Dolan from Bristol-Myers Squibb Co. There were a number of crises suffered by Bristol-Myers during the five-year tenure of Dolan as its chief executive including an accounting scandal. The company has forced Dolan to resign...

  • Apotex Pays Bristol, Sanofi $445 Million Over Plavix.  // MondayMorning;2/13/2012, Vol. 20 Issue 7, p1 

    The article informs that Apotex Corp., the biggest drugmaker of Canada, has paid 442.2 million dollar in damages to Bristol-Myers Squibb Co. and Sanofi SA for improperly selling generic version of Plavix in 2006. It is evident that in March 2002, drugmaker Bristol-Myers and Sanofi filed...

  • Despite Short-Term Revenue Hit, Sanofi Manages Patent Cliff. Powers, Marie // BioWorld International;10/31/2012, Vol. 17 Issue 44, p1 

    The article reports on the decline in the third-quarter earnings of pharmaceutical firm Sanofi SA in 2012 due to patent expirations. During the quarter, global sales of the firm's antiplatelet drug Plavix dropped by 70.1% to 568 million euros following the expiration of its patent. Information...

  • Despite Short-Term Revenue Hit, Sanofi Manages Patent Cliff. Powers, Marie // BioWorld Today;10/26/2012, Vol. 23 Issue 209, p1 

    The article reports on the decline in the third-quarter earnings of pharmaceutical firm Sanofi SA in 2012 due to patent expirations. During the quarter, global sales of the firm's antiplatelet drug Plavix dropped by 70.1% to 568 million euros following the expiration of its patent. Information...

  • Eloxatin Another Loss in Patent Portfolio.  // BioWorld Today;10/26/2012, Vol. 23 Issue 209, p5 

    The article reports on the decline in the third-quarter earnings of pharmaceutical firm Sanofi SA in 2012 due to patent expirations. During the quarter, global sales of the firm's antiplatelet drug Plavix dropped by 70.1% to 568 million euros following the expiration of its patent. Information...

  • Genzyme Focused on Niche Role in Arsenal.  // BioWorld Today;10/26/2012, Vol. 23 Issue 209, p5 

    The article reports on the decline in the third-quarter earnings of pharmaceutical firm Sanofi SA in 2012 due to patent expirations. During the quarter, global sales of the firm's antiplatelet drug Plavix dropped by 70.1% to 568 million euros following the expiration of its patent. Information...

  • Positioned for 'Bundle of Small Acquisitions.'.  // BioWorld Today;10/26/2012, Vol. 23 Issue 209, p10 

    The article reports on the decline in the third-quarter earnings of pharmaceutical firm Sanofi SA in 2012 due to patent expirations. During the quarter, global sales of the firm's antiplatelet drug Plavix dropped by 70.1% to 568 million euros following the expiration of its patent. Information...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics